The National Pharmaceuticals Strategy: Rest in peace, revive or renew?

MacKinnon, Neil J.; Ip, Ivan K.

doi:10.1503/cmaj.082087

Canadian Medical Association Journal

2009

DOI: 10.1503/cmaj.082087

|View full text |Cite

The National Pharmaceuticals Strategy: Rest in peace, revive or renew?

Neil J. MacKinnon¹,

Ivan K. Ip²

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

2019

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has been no significant progress with the federal government or industry since the report in 2006. 3 Early in 2006, the Canadian Fabry Disease Initiative (CFDI) was formed in response to an increasing demand from physicians and their patients with Fabry disease for access to an orphan drug that was available in almost every other highincome country. The CFDI was a one-of-a-kind nationwide trial that was cofunded by industry, the provinces and the federal government.…”

mentioning

confidence: 99%

Addressing the authorization of orphan drugs will not fix reimbursement problems

Embrett

2013

Can Pharm J

View full text Add to dashboard Cite

mentioning

confidence: 99%

Addressing the authorization of orphan drugs will not fix reimbursement problems

Embrett

2013

Can Pharm J

View full text Add to dashboard Cite

Access to linked administrative healthcare utilization data for pharmacoepidemiology and pharmacoeconomics research in Canada: anti‐viral drugs as an example

Rawson

2009

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

As Canada moves towards a life-cycle management approach to drug regulation, more post-marketing studies will be required, potentially using administrative data. Linked patient-level drug and healthcare data are presently accessible to pharmaceutical industry researchers in four provinces, although only logistically realistic in three and limited to seniors and low-income individuals in two. Collaborative endeavours to improve access to provincial data and to create other data resources should be encouraged.

show abstract

Building a framework for the evaluation of knowledge translation for the Canadian Network for Observational Drug Effect Studies

Sketris

Carter

Traynor

et al. 2019

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

PurposeThe Canadian Network for Observational Drug Effect Studies (CNODES), a network of pharmacoepidemiologists and other researchers from seven provincial sites, provides evidence on the benefits and risks of drugs used by Canadians. The Knowledge Translation Team, one of CNODES' four main teams, evaluates the impact of its efforts using an iterative and emergent approach. This article shares key lessons from early evaluation phases, including identifying stakeholders and their evaluation needs, choosing evaluation theories and approaches, and developing evaluation questions, designs, and methods appropriate for the CNODES context.MethodsStakeholder analysis was conducted using documentary analysis to determine key contextual factors and research evidence needs of decision maker partners and other stakeholders. Selected theories and frameworks from the evaluation and knowledge translation literature informed decisions about evaluation design and implementation. A developmental approach to evaluation was deemed appropriate due to the innovative, complex, and ever‐changing context.ResultsA theory of change, logic model, and potential evaluation questions were developed, informed by the stakeholder analysis. Early indicators of program impact (citation metrics, alternative metrics) have been documented; efforts to collect data on additional indicators are ongoing.ConclusionA flexible, iterative, and emergent evaluation approach allows the Knowledge Translation Team to apply lessons learned from completed projects to ongoing research projects, adapt its approaches based on stakeholder needs, document successes, and be accountable to funders/stakeholders. This evaluation approach may be useful for other international pharmacoepidemiology research networks planning and implementing evaluations of similarly complex, multistakeholder initiatives that are subject to constant change.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The National Pharmaceuticals Strategy: Rest in peace, revive or renew?

Cited by 5 publications

References 7 publications

Addressing the authorization of orphan drugs will not fix reimbursement problems

Addressing the authorization of orphan drugs will not fix reimbursement problems

Access to linked administrative healthcare utilization data for pharmacoepidemiology and pharmacoeconomics research in Canada: anti‐viral drugs as an example

Building a framework for the evaluation of knowledge translation for the Canadian Network for Observational Drug Effect Studies

Contact Info

Product

Resources

About